In this interactive panel of multidisciplinary experts including a dermatologist and two medical oncologists, discuss the rationale for immunotherapy in CSCC, a brief overview of mechanism of action of immunotherapy and impact on side effects as well as safety and efficacy of approved checkpoint inhibitors, and identifying patients who may benefit from immunotherapy.
Upon completion of this activity, participants should be better able to:
Associate Professor, Dermatology
Harvard Medical School
Director, Mohs and Dermatologic Surgery Center
Vice Chair, Surgical Oncology for the Department of Dermatology
Brigham and Women’s Faulkner Hospital/Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Associate Professor, Medical Oncology
University of Brescia
Brescia, Italy
Professor, Dermatology
Head, Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany
Professor, Dermatology
Head of the Oncodermatology Center
Dermatology Department
AP-HP Hôpital Saint Louis
Paris Diderot Université
INSERM U976
Paris, France
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
